Search results
Results from the WOW.Com Content Network
Dementia with Lewy bodies (DLB) is a type of dementia, a group of diseases involving progressive neurodegeneration of the central nervous system. [11] It is one of the two Lewy body dementias, along with Parkinson's disease dementia. [12] Dementia with Lewy bodies can be classified in other ways.
As of 2014, the Lewy body dementias were more often misdiagnosed than any other common dementia. [6] Most people with DLB had not heard of the condition prior to diagnosis; general awareness about LBD lags well behind that of Parkinson's and Alzheimer's diseases, even though LBD is the second most common dementia, after Alzheimer's. [6]
Scale forms on the skin surface in various disease settings, and is the result of abnormal desquamation. In pathologic desquamation, such as that seen in X-linked ichthyosis, the stratum corneum becomes thicker (hyperkeratosis), imparting a "dry" or scaly appearance to the skin, and instead of detaching as single cells, corneocytes are shed in clusters, which forms visible scales. [2]
Gout in foot joints is most common, with gout often affecting the big toe joint. However, other joints can be affected as well, particularly those in the lower body. For example, gout in ankles or ...
Symptoms include inflamed skin, diarrhea, dementia, and sores in the mouth. [1] Areas of the skin exposed to friction and radiation are typically affected first. [1] Over time affected skin may become darker, stiffen, peel, or bleed. [1] [3] There are two main types of pellagra, primary and secondary. [1]
The signs, symptoms and cognitive profile of PDD are similar to those of DLB; [2] DLB and PDD are clinically similar after dementia occurs in Parkinson's disease. [5] Parkinson's disease is a risk factor for PDD; it speeds up decline in cognition leading to PDD. [2] Up to 78% of people with PD have dementia. [2]
Health officials in Europe are investigating Ozempic and the trendy drug’s possible link to an eye-rotting condition that causes blindness. On Dec. 17, the European Medicines Agency announced ...
For premium support please call: 800-290-4726 more ways to reach us